CN114728167B - 作为δ-5脱饱和酶抑制剂的杂环化合物以及使用方法 - Google Patents

作为δ-5脱饱和酶抑制剂的杂环化合物以及使用方法 Download PDF

Info

Publication number
CN114728167B
CN114728167B CN202080081465.8A CN202080081465A CN114728167B CN 114728167 B CN114728167 B CN 114728167B CN 202080081465 A CN202080081465 A CN 202080081465A CN 114728167 B CN114728167 B CN 114728167B
Authority
CN
China
Prior art keywords
trifluoromethyl
pyrimidin
methyl
pyrazol
imidazo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080081465.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN114728167A (zh
Inventor
J·R·艾伦
M·贝尔特尼
M·P·布尔博
T·P·黛米娅诺娃
I·林加德
A·E·米娜提
P·温塞提
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Priority to CN202410291075.3A priority Critical patent/CN118161500A/zh
Publication of CN114728167A publication Critical patent/CN114728167A/zh
Application granted granted Critical
Publication of CN114728167B publication Critical patent/CN114728167B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN202080081465.8A 2019-11-25 2020-11-24 作为δ-5脱饱和酶抑制剂的杂环化合物以及使用方法 Active CN114728167B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202410291075.3A CN118161500A (zh) 2019-11-25 2020-11-24 作为δ-5脱饱和酶抑制剂的杂环化合物以及使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962939821P 2019-11-25 2019-11-25
US62/939,821 2019-11-25
PCT/US2020/062020 WO2021108408A1 (en) 2019-11-25 2020-11-24 Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202410291075.3A Division CN118161500A (zh) 2019-11-25 2020-11-24 作为δ-5脱饱和酶抑制剂的杂环化合物以及使用方法

Publications (2)

Publication Number Publication Date
CN114728167A CN114728167A (zh) 2022-07-08
CN114728167B true CN114728167B (zh) 2024-03-19

Family

ID=73855555

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202080081465.8A Active CN114728167B (zh) 2019-11-25 2020-11-24 作为δ-5脱饱和酶抑制剂的杂环化合物以及使用方法
CN202410291075.3A Pending CN118161500A (zh) 2019-11-25 2020-11-24 作为δ-5脱饱和酶抑制剂的杂环化合物以及使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202410291075.3A Pending CN118161500A (zh) 2019-11-25 2020-11-24 作为δ-5脱饱和酶抑制剂的杂环化合物以及使用方法

Country Status (21)

Country Link
US (3) US11512097B2 (enExample)
EP (1) EP4065223A1 (enExample)
JP (2) JP7254246B2 (enExample)
KR (2) KR20230154292A (enExample)
CN (2) CN114728167B (enExample)
AR (1) AR120556A1 (enExample)
AU (1) AU2020392087B2 (enExample)
BR (1) BR112022010054A2 (enExample)
CA (1) CA3162281A1 (enExample)
CL (2) CL2022001357A1 (enExample)
CO (1) CO2022008690A2 (enExample)
CR (1) CR20220308A (enExample)
IL (1) IL293191B2 (enExample)
JO (1) JOP20220125A1 (enExample)
MX (1) MX2022006281A (enExample)
PE (1) PE20231097A1 (enExample)
PH (1) PH12022551282A1 (enExample)
SA (1) SA522432710B1 (enExample)
TW (2) TWI815061B (enExample)
UY (1) UY38971A (enExample)
WO (1) WO2021108408A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11220510B2 (en) * 2018-04-09 2022-01-11 Incyte Corporation Pyrrole tricyclic compounds as A2A / A2B inhibitors
PH12022551282A1 (en) * 2019-11-25 2023-11-29 Amgen Inc Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use
CN115557903A (zh) * 2022-09-27 2023-01-03 山东潍坊润丰化工股份有限公司 一种特草定的制备方法
TW202434254A (zh) 2022-11-23 2024-09-01 美商安進公司 選擇用於fads1調節劑治療的患者之方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102015715A (zh) * 2008-04-23 2011-04-13 葛兰马克制药公司 作为trpv3调节剂的稠合嘧啶酮
WO2011114148A1 (en) * 2010-03-17 2011-09-22 Astrazeneca Ab 4h- [1, 2, 4] triazolo [5, 1 -b] pyrimidin-7 -one derivatives as ccr2b receptor antagonists
CN106749271A (zh) * 2016-12-07 2017-05-31 青岛科技大学 一类[1,2,4]‑三氮唑并[1,5‑a]嘧啶酮类杂环化合物、其制备方法及其用途
WO2018039972A1 (en) * 2016-08-31 2018-03-08 Agios Pharmaceuticals, Inc. Inhibitors of cellular metabolic processes

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3130633A1 (de) 1981-08-01 1983-02-17 Basf Ag, 6700 Ludwigshafen 7-amino-azolo(1,5-a)pyrimidine und diese enthaltende fungizide
JP2641443B2 (ja) 1986-04-07 1997-08-13 クミアイ化学工業株式会社 ５Ｈ−１，３，４−チアジアゾロ〔３，２−ａ〕ピリミジン−５−オン誘導体及びこれを有効成分とする農園芸用殺菌剤
US6096753A (en) 1996-12-05 2000-08-01 Amgen Inc. Substituted pyrimidinone and pyridone compounds and methods of use
CN1328277C (zh) 1996-12-05 2007-07-25 安姆根有限公司 取代的嘧啶酮和吡啶酮化合物和它们的应用
CA2386942A1 (en) 1999-10-15 2001-04-26 Neurocrine Biosciences, Inc. Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
US6537998B1 (en) * 1999-10-15 2003-03-25 Neurocrine Biosciences, Inc. Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
AU2003238157A1 (en) 2002-06-18 2003-12-31 Sankyo Company, Limited Fused-ring pyrimidin-4(3h)-one derivatives, processes for the preparation and uses thereof
JP2004107228A (ja) 2002-09-17 2004-04-08 Nippon Nohyaku Co Ltd 双環性ピリミジノン誘導体及びこれを有効成分とする除草剤
PE20051089A1 (es) 2004-01-22 2006-01-25 Novartis Ag Derivados de pirazolo [1,5-a] pirimidin-7-il-amina como inhibidores de quinasa de proteina
US20050222171A1 (en) 2004-01-22 2005-10-06 Guido Bold Organic compounds
WO2006067401A1 (en) 2004-12-24 2006-06-29 Astrazeneca Ab Heterocyclic compounds as ccr2b antagonists
WO2007002701A2 (en) 2005-06-27 2007-01-04 Amgen Inc. Anti-inflammatory aryl nitrile compounds
WO2007027012A1 (en) 2005-07-18 2007-03-08 Samsung Electronics Co., Ltd. Video coding method and apparatus for reducing mismatch between encoder and decoder
AU2006274075A1 (en) 2005-07-27 2007-02-01 Basf Se Fungicide 6-phenyl-triazolopyrimidinyl amines
JP2009502864A (ja) 2005-07-27 2009-01-29 ビーエーエスエフ ソシエタス・ヨーロピア 殺菌性の５−メチル−６−フェニルトリアゾロピリミジニルアミン
BRPI0614104A2 (pt) 2005-07-27 2016-11-22 Basf Ag compostos, processo para preparar compostos, agente fungicida, semente, e, processo para combater fungos nocivos fitopatogênicos
BRPI0616985B1 (pt) 2005-10-06 2021-10-26 Merck Sharp & Dohme Corp. Composto de pirazolo[1,5-a]pirimidina, e, uso de um composto
KR20090073120A (ko) 2006-09-28 2009-07-02 노파르티스 아게 피라졸로[1,5-ａ]피리미딘 유도체 및 이들의 치료 용도
JP2010505881A (ja) 2006-10-05 2010-02-25 ギリアード・パロ・アルト・インコーポレイテッド ステアロイルＣｏＡデサチュラーゼインヒビターとして使用するための二環式窒素含有複素環式化合物
US8173661B2 (en) 2006-11-08 2012-05-08 The Rockefeller University Alpha-IIB-beta-3 inhibitors and uses thereof
WO2008089307A2 (en) 2007-01-18 2008-07-24 Lexicon Pharmaceuticals, Inc. Delta 5 desaturase inhibitors for the treatment of pain, inflammation and cancer
US20080200458A1 (en) 2007-01-18 2008-08-21 Joseph Barbosa Methods and compositions for the treatment of body composition disorders
BRPI0806347A2 (pt) 2007-01-19 2011-09-06 Basf Se misturas fungicidas, agente fungicida, método para combater fungos nocivos fitopagênicos, semente, e, processo para preparar um agente
WO2008092836A2 (en) 2007-01-30 2008-08-07 Basf Se Method for improving plant health
BRPI0809045A2 (pt) 2007-03-23 2014-09-02 Basf Se Combinações de substância ativa, uso de combinações de substância ativa, métodos para combater fungos fitopatogênicos indesejáveis, para preparar agentes pesticidas, e para tratar sementes, e, produto de revestimento de semente
CA2709784A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
JP2011516496A (ja) 2008-04-04 2011-05-26 ギリアード サイエンシーズ， インコーポレイテッド ステアロイル−ＣｏＡデサチュラーゼの阻害剤として使用するためのピロロトリアジノン誘導体
US20100099561A1 (en) 2008-10-15 2010-04-22 E.I. Du Pont De Nemours And Company Heterobicyclic alkylthio-bridged isoxazolines
US20100190747A1 (en) 2009-01-27 2010-07-29 Hideo Suzuki Fused ring compound and use thereof
HRP20140754T2 (hr) 2009-06-29 2015-07-17 Incyte Corporation Pirimidinoni kao inhibitori pi3k
JPWO2012011592A1 (ja) 2010-07-23 2013-09-09 武田薬品工業株式会社 複素環化合物およびその用途
WO2012125629A1 (en) 2011-03-14 2012-09-20 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
US8952012B2 (en) 2012-05-24 2015-02-10 Colorado State University Research Foundation Inhibition of delta-6 desaturase for the treatment of cardiometabolic disease
US20140275092A1 (en) 2013-03-13 2014-09-18 Constellation Pharmaceuticals, Inc. Pyrazolo compounds and uses thereof
US9505767B2 (en) 2013-09-05 2016-11-29 Genentech, Inc. Pyrazolo[1,5-A]pyrimidin-7(4H)-onehistone demethylase inhibitors
WO2015064714A1 (ja) 2013-10-31 2015-05-07 国立大学法人東京大学 オートタキシン阻害活性を有する１－置換イミダゾピリミジノン誘導体
WO2015135094A1 (en) 2014-03-13 2015-09-17 Genentech, Inc. Therapeutic compounds and uses thereof
KR102458990B1 (ko) 2014-04-23 2022-10-25 미쓰비시 타나베 파마 코퍼레이션 신규한 바이시클릭 또는 트리시클릭 헤테로시클릭 화합물
WO2016183063A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Crystalline forms of a pi3k inhibitor
JP6791717B2 (ja) 2015-10-22 2020-11-25 田辺三菱製薬株式会社 医薬組成物
JP2017091808A (ja) 2015-11-10 2017-05-25 株式会社フジクラ 酸化物超電導線材の製造方法及び超電導コイルの製造方法
EP3394032A4 (en) 2015-12-21 2019-09-18 The University of Chicago COMPOUNDS AND METHODS OF TREATMENT, DETECTION AND IDENTIFICATION OF COMPOUNDS FOR THE TREATMENT OF PARASITIC ILLNESSES BY APICOMPLEXA
MX390277B (es) 2016-08-31 2025-03-20 Servier Lab Inhibidores de procesos metabolicos celulares.
SG11201910197SA (en) 2017-05-15 2019-11-28 Dana Farber Cancer Inst Inc Compounds for treating dengue virus infection and other viral infections
WO2018229683A1 (en) 2017-06-15 2018-12-20 Novartis Ag 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases
KR20200032751A (ko) 2017-09-15 2020-03-26 아두로 바이오테크, 인코포레이티드 피라졸로피리미디논 화합물 및 그의 용도
PH12022551282A1 (en) 2019-11-25 2023-11-29 Amgen Inc Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102015715A (zh) * 2008-04-23 2011-04-13 葛兰马克制药公司 作为trpv3调节剂的稠合嘧啶酮
WO2011114148A1 (en) * 2010-03-17 2011-09-22 Astrazeneca Ab 4h- [1, 2, 4] triazolo [5, 1 -b] pyrimidin-7 -one derivatives as ccr2b receptor antagonists
WO2018039972A1 (en) * 2016-08-31 2018-03-08 Agios Pharmaceuticals, Inc. Inhibitors of cellular metabolic processes
CN106749271A (zh) * 2016-12-07 2017-05-31 青岛科技大学 一类[1,2,4]‑三氮唑并[1,5‑a]嘧啶酮类杂环化合物、其制备方法及其用途

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
L’acide déhydracétique, précurseur de nouvelles pyridopyrimidines, thiazolopyrimidines et pyridones;Bahia Djerrari等;Comptes Rendus Chimie;第5卷(第3期);177-183 *
Reaction of 1-substituted 3,5-diamino-1,2,4-triazoles with β-keto esters: synthesis and new rearrangement of mesoionic 3-amino-2H-[1,2,4]triazolo-[4,3-a]pyrimidin-5-ones;Victor M. Chernyshev;Tetrahedron;第66卷(第18期);3301-3313 *

Also Published As

Publication number Publication date
CR20220308A (es) 2022-08-04
US11512097B2 (en) 2022-11-29
AU2020392087B2 (en) 2025-10-23
US20210221824A1 (en) 2021-07-22
PH12022551282A1 (en) 2023-11-29
TW202132317A (zh) 2021-09-01
BR112022010054A2 (pt) 2022-08-16
CL2022001357A1 (es) 2023-03-10
TW202409042A (zh) 2024-03-01
IL293191B1 (en) 2025-05-01
US12448396B2 (en) 2025-10-21
WO2021108408A1 (en) 2021-06-03
TWI815061B (zh) 2023-09-11
IL293191A (en) 2022-07-01
TWI867822B (zh) 2024-12-21
CL2023002486A1 (es) 2024-01-12
CN114728167A (zh) 2022-07-08
KR102598203B1 (ko) 2023-11-03
JP7698676B2 (ja) 2025-06-25
MX2022006281A (es) 2022-06-08
JP7254246B2 (ja) 2023-04-07
US20210188874A1 (en) 2021-06-24
CN118161500A (zh) 2024-06-11
JP2023078418A (ja) 2023-06-06
CO2022008690A2 (es) 2022-06-30
US20230159560A1 (en) 2023-05-25
IL293191B2 (en) 2025-09-01
AU2020392087A1 (en) 2022-06-09
UY38971A (es) 2021-06-30
KR20220106159A (ko) 2022-07-28
JP2022549739A (ja) 2022-11-28
SA522432710B1 (ar) 2025-05-29
KR20230154292A (ko) 2023-11-07
AR120556A1 (es) 2022-02-23
CA3162281A1 (en) 2021-06-03
EP4065223A1 (en) 2022-10-05
JOP20220125A1 (ar) 2023-01-30
PE20231097A1 (es) 2023-07-18

Similar Documents

Publication Publication Date Title
CN114728167B (zh) 作为δ-5脱饱和酶抑制剂的杂环化合物以及使用方法
TWI482774B (zh) 作爲ＬＲＲＫ２抑制劑之新穎４－（經取代胺基）－７Ｈ－吡咯并［２，３－ｄ］嘧啶類
CN101687876B (zh) 氨基杂环化合物
TWI734134B (zh) 作為trk激酶抑制劑的大環化合物
JP7638987B2 (ja) デルタ－５デサチュラーゼ阻害剤としての複素環式化合物、及び使用法
EA048401B1 (ru) Гетероциклические соединения в качестве ингибиторов дельта-5-десатуразы и способы применения
WO2022166796A1 (zh) 嘧啶或吡啶并杂环类腺苷受体抑制剂及其制备方法和用途
JP2017075116A (ja) 新規縮合複素環化合物
HK1213885B (en) Imidazo-triazine derivatives as pde10 inhibitors
HK1213885A1 (zh) 作爲pde10抑制剂的咪唑并-三嗪衍生物
HK1204619B (en) 4-(substituted-amino)-7h-pyrrolo[2,3-d]pyrimidines as lrrk2 inhibitors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant